The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis

Scandinavian Journal of Gastroenterology

Volumn 51, Issue 12, 2016, Pages 1407-1415

  Prosberg, Michelle ^a   Bendtsen, Flemming ^a   Vind, Ida ^a   Petersen, Andreas M ^a   Gluud, Lise L ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

clinical trials; Crohn s disease; dysbiosis; faecal microbiota; Ulcerative colitis

Indexed keywords

BIFIDOBACTERIUM; CLOSTRIDIUM; CLOSTRIDIUM COCCOIDES; CLOSTRIDIUM LEPTUM; CROHN DISEASE; DENATURING GRADIENT GEL ELECTROPHORESIS; DISEASE ACTIVITY; ESCHERICHIA COLI; FAECALIBACTERIUM PRAUSNITZII; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTESTINE FLORA; LACTOBACILLUS; META ANALYSIS; NEWCASTLE OTTAWA SCALE; NONHUMAN; NUCLEIC ACID ANALYSIS; POPULATION ABUNDANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SYSTEMATIC REVIEW; TERMINAL RESTRICTION FRACTION LENGTH POLYMORPHISM; ULCERATIVE COLITIS; DYSBIOSIS; FAECALIBACTERIUM; FECES; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOPHYSIOLOGY;

BIFIDOBACTERIUM; CLOSTRIDIUM; COLITIS, ULCERATIVE; CROHN DISEASE; DYSBIOSIS; FAECALIBACTERIUM; FECES; GASTROINTESTINAL MICROBIOME; HUMANS; REMISSION INDUCTION;

EID: 84991712942     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365521.2016.1216587     Document Type: Review

References (56)

1. J.Babickova, R.Gardlik Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease. World J Gastroenterol. 2015;21:11321–11330.
2. A.D.Kostic, R.J.Xavier, D.Gevers The microbiome in inflammatory bowel disease:current status and the future ahead. Gastroenterology. 2014;146:1489–1499.
3. M.K.Vester-Andersen, M.V.Prosberg, T.Jess,. Disease course and surgery rates in inflammatory bowel disease:a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol. 2014;109:705–714.
4. I.Vind, L.Riis, T.Jess,. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005:a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101:1274–1282.
5. K.L.Wallace, L.B.Zheng, Y.Kanazawa,. Immunopathology of inflammatory bowel disease. World J Gastroenterol. 2014;20:6–21.
6. W.Strober, I.Fuss, P.Mannon The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117:514–521.
7. B.Khor, A.Gardet, R.J.Xavier Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–317.
8. S.R.Gill, M.Pop, R.T.Deboy,. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312:1355–1359.
9. L.Jostins, S.Ripke, R.K.Weersma,. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–124.
10. J.D.Taurog, J.A.Richardson, J.T.Croft,. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180:2359–2364.
11. R.K.Sellon, S.Tonkonogy, M.Schultz,. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66:5224–5231.
12. D.N.Frank, A.L.St Amand, R.A.Feldman,. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104:13780–13785.
13. H.Sokol, P.Seksik, L.Rigottier-Gois,. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:106–111.
14. D.A.Peterson, D.N.Frank, N.R.Pace,. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe. 2008;3:417–427.
15. S.J.Ott, M.Musfeldt, D.F.Wenderoth,. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53:685–693.
16. C.Manichanh, L.Rigottier-Gois, E.Bonnaud,. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006;55:205–211.
17. M.Baumgart, B.Dogan, M.Rishniw,. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn’s disease involving the ileum. ISME J. 2007;1:403–418.
18. U.Gophna, K.Sommerfeld, S.Gophna,. Differences between tissue-associated intestinal microfloras of patients with Crohn’s disease and ulcerative colitis. J Clin Microbiol. 2006;44:4136–4141.
19. P.Seksik, L.Rigottier-Gois, G.Gramet,. Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon. Gut. 2003;52:237–242.
20. C.Lupp, M.L.Robertson, M.E.Wickham,. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe. 2007;2:119–129.
21. A.Liberati, D.G.Altman, J.Tetzlaff,. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions:explanation and elaboration. BMJ. 2009;339:b2700.
22. G.A.Wells, B.Shea, D.O’Connell,. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [cited 2016 Feb 1]. Available from:http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. 2015.
23. A.Nikolakopoulou, D.Mavridis, G.Salanti Demystifying fixed and random effects meta-analysis. Evid Based Ment Health. 2014;17:53–57.
24. P.Moayyedi, M.G.Surette, P.T.Kim,. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102–109. e106.
25. N.G.Rossen, S.Fuentes, M.J.van der Spek,. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110–118. e114.
26. D.L.Suskind, N.Singh, H.Nielson,. Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2015;60:27–29.
27. S.L.James, C.T.Christophersen, A.R.Bird,. Abnormal fibre usage in UC in remission. Gut. 2015;64:562–570.
28. A.O.Jigaranu, O.Nedelciuc, A.Blaj,. Is rifaximin effective in maintaining remission in Crohn’s disease? Dig Dis. 2014;32:378–383.
29. E.Varela, C.Manichanh, M.Gallart,. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment Pharmacol Ther. 2013;38:151–161.
30. A.Andoh, H.Kuzuoka, T.Tsujikawa,. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease. J Gastroenterol. 2012;47:1298–1307.
31. W.Wang, L.Chen, R.Zhou,. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol. 2014;52:398–406.
32. S.Sha, B.Xu, X.Wang,. The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel disease. Diagn Microbiol Infect Dis. 2013;75:245–251.
33. L.K.Vigsnaes, J.Brynskov, C.Steenholdt,. Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls. Benef Microbes. 2012;3:287–297.
34. A.Swidsinski, V.Loening-Baucke, M.Vaneechoutte,. Active Crohn’s disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis. 2008;14:147–161.
35. H.Sokol, P.Seksik, J.P.Furet,. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009;15:1183–1189.
36. H.Takaishi, T.Matsuki, A.Nakazawa,. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol. 2008;298:463–472.
37. R.Kumari, V.Ahuja, J.Paul Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India. World J Gastroenterol. 2013;19:3404–3414.
38. S.Rajca, V.Grondin, E.Louis,. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn’s disease. Inflamm Bowel Dis. 2014;20:978–986.
39. N.Dey, D.A.Soergel, S.Repo,. Association of gut microbiota with post-operative clinical course in Crohn’s disease. BMC Gastroenterol. 2013;13:131.
40. P.De Cruz, S.Kang, J.Wagner,. Association between specific mucosa-associated microbiota in Crohn’s disease at the time of resection and subsequent disease recurrence:a pilot study. J Gastroenterol Hepatol. 2015;30:268–278.
41. A.Fite, S.Macfarlane, E.Furrie,. Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration. J Clin Microbiol. 2013;51:849–856.
42. S.J.Ott, S.Plamondon, A.Hart,. Dynamics of the mucosa-associated flora in ulcerative colitis patients during remission and clinical relapse. J Clin Microbiol. 2008;46:3510–3513.
43. M.Lopez-Siles, M.Martinez-Medina, D.Busquets,. Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotypes. Int J Med Microbiol. 2014;304:464–475.
44. J.Kabeerdoss, V.Sankaran, S.Pugazhendhi,. Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease:a case-control study in India. BMC Gastroenterol. 2013;13:20.
45. K.Machiels, M.Joossens, J.Sabino,. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–1283.
46. W.R.Best, J.M.Becktel, J.W.SingletonJr.,. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–444.
47. J.D.Lewis, S.Chuai, L.Nessel,. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.
48. G.Bouma, W.Strober The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521–533.
49. J.P.Hugot, M.Chamaillard, H.Zouali,. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411:599–603.
50. A.Franke, D.P.McGovern, J.C.Barrett,. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42:1118–1125.
51. P.J.Turnbaugh, M.Hamady, T.Yatsunenko,. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–484.
52. D.Knights, K.G.Lassen, R.J.Xavier Advances in inflammatory bowel disease pathogenesis:linking host genetics and the microbiome. Gut. 2013;62:1505–1510.
53. D.C.Vinh, M.A.Behr Crohn’s as an immune deficiency:from apparent paradox to evolving paradigm. Expert Rev Clin Immunol. 2013;9:17–30.
54. G.L.Hold, M.Smith, C.Grange,. Role of the gut microbiota in inflammatory bowel disease pathogenesis:what have we learnt in the past 10 years? World J Gastroenterol. 2014;20:1192–1210.
55. V.Leone, E.B.Chang, S.Devkota Diet, microbes, and host genetics:the perfect storm in inflammatory bowel diseases. J Gastroenterol. 2013;48:315–321.
56. D.N.Frank, C.E.Robertson, C.M.Hamm,. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:179–184.